

Yuxin Zhong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6637697/publications.pdf>

Version: 2024-02-01

8
papers

98
citations

1937685
4
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

118
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Differentially Expressed Genes. <i>International Journal of Biological Sciences</i> , 2020, 16, 1153-1165.	6.4	45
2	Value of quantitative dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging in predicting extramural venous invasion in locally advanced gastric cancer and prognostic significance. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 328-340.	2.0	17
3	<p>Metastasectomy Improves the Survival of Gastric Cancer Patients with Krukenberg Tumors: A Retrospective Analysis of 182 patients</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10573-10580.	1.9	13
4	<p>Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5141-5146.	1.9	12
5	Prognostic Significance of Signet Ring Cells in Gastric Cancer: The Higher Proportion, The Better Survival. <i>Frontiers in Oncology</i> , 2021, 11, 713587.	2.8	4
6	Quantitative Dynamic-Enhanced MRI and Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Prediction of the Pathological Response to Neoadjuvant Chemotherapy and the Prognosis in Locally Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 841460.	2.8	4
7	Is subtotal gastrectomy feasible for the treatment of gastric stump cancer located at the anastomotic site after distal gastrectomy for benign lesions?. <i>World Journal of Surgical Oncology</i> , 2020, 18, 43.	1.9	2
8	Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): An open-label, randomized, phase 2 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4031-4031.	1.6	1